Intermittent fasting after ST-elevation myocardial infarction to improve left ventricular function

Intermittent fasting after ST-elevation myocardial infarction to improve left ventricular function - INTERFAST-MI

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00021784

Enrollment

Registered

2020-09-24

Start date

2020-10-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I21

Interventions

Group 1: Intermittent Fasting (time-restricted feeding

at least 16 hours fasting, not more than 8 hours unrestricted diet) for three months

then voluntary continuation of intermittent fasting or cross-over for three more months Group 2: Control (no specific dietary restrictions) for three months, the voluntary cross-over or three more mon

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - written informed consent - ST-elevation myocardial infarction (or equivalent)

Exclusion criteria

Exclusion criteria: - missing informed consent - participation in other clinical trials - patients with cardiac devices not approved for MRI scanning - kidney failure (GFR <30 ml/min) - claustrophobia - antidiabetic therapy with sulfonylurea - pregnancy - employees of the study center

Design outcomes

Primary

Measure	Time frame
Left ventricular myocardial function at four weeks after randomization (evaluated by echocardiography)	—

Secondary

Measure	Time frame
- all-cause hospitalization - hospitalization from cardiovascular cause - all-cause death - death from cardiovascular cause - myocardial infarction - revascularisation - stroke - patient weight - blood pressure - medication - comorbidities - left ventricular function at three and six months after randomization - further characterization of myocardial function evaluated by echocardiography (i.e. Kinetikstörungen, LVEDP, E/e‘) - myocardial scar and edema (evaluated by cardiac MRI) - clinical chemistry and hematology (hGH, adiponectine, NT-proBNP, creatinine, fasting insulin, fasting blood glucose, HbA1c, blood count, IL-1, IL-6, C-reactive protein, homocysteine, cholesterine, LDL, HDL, triglycerides) - Peripheral Blood Mononuclear Cells - DNA-Methylation of circulating cells („epigenetic clock“) Follow-up: 6 months. Study visits at regular ambulatory visits at 4 weeks, 3 months, and 6 months	—

Measure

Time frame

- all-cause hospitalization - hospitalization from cardiovascular cause - all-cause death - death from cardiovascular cause - myocardial infarction - revascularisation - stroke - patient weight - blood pressure - medication - comorbidities - left ventricular function at three and six months after randomization - further characterization of myocardial function evaluated by echocardiography (i.e. Kinetikstörungen, LVEDP, E/e‘) - myocardial scar and edema (evaluated by cardiac MRI) - clinical chemistry and hematology (hGH, adiponectine, NT-proBNP, creatinine, fasting insulin, fasting blood glucose, HbA1c, blood count, IL-1, IL-6, C-reactive protein, homocysteine, cholesterine, LDL, HDL, triglycerides) - Peripheral Blood Mononuclear Cells - DNA-Methylation of circulating cells („epigenetic clock“) Follow-up: 6 months. Study visits at regular ambulatory visits at 4 weeks, 3 months, and 6 months

—

Countries

Germany

Contacts

Public ContactJochen Dutzmann

Universitätsklinikum Halle (Saale)

jochen.dutzmann@uk-halle.de+49(0)345/557-2457

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 12, 2026